Department of Eating and Weight Disorders, Villa Garda Hospital
Garda, Italy, 37016
Location status: Recruiting
NCT Number: NCT05290285
Amino acids (AAs) are crucial for protein synthesis, in influencing nutritional status, as sources of vital elements (e.g., nucleotides, neurotransmitters) and as signal molecules for the modulation of gene expression and epigenetic mechanisms. Data on the role of amino acids in underweight patients with anorexia nervosa (AN) are unknown. This study aims to evaluate whether a blend of essential amino acids (EAA) could influence the change in lean body mass (LBM) in patients with AN during weight restoration, treated with intensive inpatient enhanced cognitive behavior therapy (CBT-E). A total of 92 patients will be randomized to EAA supplementation or placebo supplementation upon admission to inpatient treatment. LBM, but also body weight, specific and general psychopathology, impairment assessment will be assessed at baseline and after 13 weeks of treatment.
Interested in participating?
Request Info16 year–50 year
All sexes
Interventional
Not applicable
Garda, Italy, 37016
Location status: Recruiting
Nutrition is one of the main determinants of health. Among the three primary macronutrients, proteins - specifically, their quantity and quality (i.e., their specific amino acid profile) - play a crucial role in regulating metabolic health and longevity. Amino acids (AAs) are crucial not only for protein synthesis and influencing nutritional status but also as sources of vital elements (e.g., nucleotides, neurotransmitters) and as signal molecules for the modulation of gene expression and epigenetic mechanisms. To our knowledge, only one study was conducted on underweight patients with anorexia nervosa (AN). The study design was to compare the efficacy of the semi-essential amino acid L-tyrosine (100 mg/kg/day) versus a placebo supplement. Tyrosine reduced reaction time and test duration in memory tasks and improved mood. However, to date, no studies have evaluated the effect of supplementation with amino acids in patients with anorexia nervosa who undergo specialist treatment aimed at weight recovery and remission from psychopathology.
The study has the primary aim of evaluating the effectiveness of supplementation with essential amino acids (EAA) on the change in lean body mass (LBM) with weight recovery in patients with AN treated with specialist treatment for eating disorders, compared to placebo supplementation. The secondary aims of the study are to evaluate the effectiveness of EAA supplementation on physical fitness, weight recovery, change of the general and eating disorder psychopathology, and psychosocial impairment, compared to placebo supplementation.
A 13-week randomized double-blind placebo-controlled study design will be used.
Patients will be randomized to EAA supplementation or placebo supplementation upon admission. Randomization will be carried out by an independent external figure adopting the following stratification:
Group 1: Body Mass Index (BMI) <= 15.2 & age <= 20 Group 2: BMI > 15.2 & age <= 20 Group 3: BMI <= 15.2 & age > 20 Group 4: BMI > 15.2 & age > 20 Treatment will involve a 13-week inpatient or a 13-week day hospital. Follow-up will be performed for both groups at 24 weeks. Considering that it will not be possible to carry out a closed follow-up, we will give the possibility to those who have taken the mixture of EAA to continue this treatment after the end of inpatient or day-hospital, for other 24 weeks, to evaluate the potential long-term maintenance of the treatment.
The study is performed at the Nutritional Rehabilitation Unit of the Villa Garda Hospital - Italy.
The supervision of the diagnostic evaluation and treatment is carried out weekly by the Director of the Nutritional Rehabilitation Unit of the Villa Garda Hospital.
Study participants will be recruited from patients who meet the diagnostic criteria for AN, assessed with the Eating Disorder Examination (EDE.17) interview, consecutively admitted at the Nutritional Rehabilitation Unit of the Villa Garda Hospital. All participants will meet the appropriateness criteria of hospitalization established by the Veneto Region and described in table 1 of Annex B of DGR 94/2012.
On the entry day into the Nutritional Rehabilitation Unit, the patient will meet a unit physician for the medical history collection, the physical examination, and the prescription of humoral and instrumental examinations. On this occasion, the enrollment phase will take place which will include the complete collection of data for the compilation of the Data Collection Form. At the end of the data collection, if the criteria for inclusion in the study are met, the patient will receive detailed information on:
Before requesting to sign the informed consent and the possibility of using (and having consent to use) the information collected during the trial, the patient will be given a statement to read containing detailed information on the study.
If the patient, or in the case of a minor patient, his/her parents (s), and/or legal guardians (s), agrees to participate in the study, he/she will sign the informed consent form and the authorization to process personal and sensitive data.
If the patient meets the criteria for inclusion in the study but refuses to participate in the study, he/she will continue the intensive rehabilitation treatment applied at the Nutritional Rehabilitation Unit of the Villa Garda Hospital.
After the interview and signing the informed consent and data processing, the patient will be randomized to EAA supplementation or placebo supplementation. Both arms will receive enhanced cognitive behavior therapy (CBT-E).
The intensive CBT-E applied at the Nutritional Rehabilitation Unit of the Villa Garda Hospital has been described in national and international publications. The treatment is based on the transdiagnostic cognitive-behavioral theory and therapy of eating disorders developed by the Center for Research on Eating Disorders and Obesity of the University of Oxford.
The inpatient treatment includes 13 weeks, followed by seven weeks of day-hospital, and is divided into four phases that are individualized to address the maintenance mechanisms of the eating disorder psychopathology operating in the individual patient.
The nutritional rehabilitation protocol of the Villa Garda Hospital applied to underweight patients with AN is as follows:
Afterward:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Food supplements
Maltodextrin
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Percentage change in patient's lean body mass with weight gain at the end of hospital treatment, measured using the DXA (Prodigy Primo Lunar, A223040501, General Electric Company, Madison. WI 53707-7550, USA-EnCORE TM 2009 (v13.31) software)
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Change in physical fitness measured using the Eurofit Physical Fitness Test Battery (EPFTB) (EUROFIT Strasbourg: Council of Europe; 1993
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Change in body weight measured using the Seca Digital Wheelchair Scale Model 664 [Seca, Hamburg, Germany]
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Change in eating disorder psychopathology measured using the Eating Disorder Examination Questionnaire (EDE-Q) (Calugi, Milanese, et al., 2017; Fairburn & Beglin, 2008).
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Change in general psychopathology measured using the Brief Symptom Inventory (BSI) (De Leo, Frisoni, Rozzini, & Trabucchi, 1993; Derogatis & Spencer, 1982).
Time frame: From baseline (admission to inpatient) to end of hospitalization (after 13 weeks)
Change in clinical impairment measured using the Clinical Impairment Assessment (CIA) (Bohn et al., 2008; Calugi et al., 2018).
Contact information is provided by the study sponsor or research team.
Villa Garda Hospital
Other
Efficacy and Tolerability of a Specific Blend of Amino Acids in Patients With Anorexia Nervosa Treated in a Hospital Setting. Double-blind Randomized Study Versus Placebo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07600671
Anorexia Nervosa, Binge Eating Disorder
Lebanon, New Hampshire, United States
View Trial DetailsNCT05918835
Anorexia Nervosa, Feeding and Eating Disorders
New York, United States
View Trial DetailsNCT06594913
Anorexia Nervosa, Avoidant Restrictive Food Intake Disorder
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05763849
Anorexia Nervosa, Feeding and Eating Disorders
New York, United States
View Trial Details